Tourmaline_logo.jpg
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
May 16, 2024 07:00 ET | Tourmaline Bio, Inc.
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
NOVARTIS logo.jpg
Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA
May 15, 2024 10:00 ET | Novartis Pharma AG
Primary results of the Scemblix® ASC4FIRST pivotal Phase III study in first-line Ph+ CML-CP supporting third US FDA Breakthrough Therapy designation, to be detailed in the ASCO Press Program and the...
CITELINE_LOGO_FULL COLOUR_RGB.png
Citeline Introduces Global Patient Insights
May 15, 2024 09:00 ET | Citeline
Citeline announces the launch of Global Patient Insights, the industry’s most comprehensive view of the worldwide patient landscape.
Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
May 15, 2024 08:05 ET | Third Harmonic Bio
U.S. FDA clears Investigational New Drug application for THB335 Phase 1 SAD/MAD clinical trial initiated and subject screening underway, with results expected during 1H’25 Strengthened leadership...
22157.jpg
Global PIM Kinase Targeted Therapies Market Opportunity & Clinical Trials Report 2024: USA Dominating with 5 Therapies, FDA Orphan Designation, Proprietary Development Technologies by Companies
May 14, 2024 05:38 ET | Research and Markets
Dublin, May 14, 2024 (GLOBE NEWSWIRE) -- The "Global PIM Kinase Targeted Therapies Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering....
Science 37 Logo.jpg
Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance
May 13, 2024 08:00 ET | Science 37, Inc.
Science 37 Holdings, Inc. today announced the preliminary outcome of its recent FDA Inspection focusing on critical areas and documentation.
New 2024 TrialWire Logo (600 x 500 px) (400 x 100 px) (600 x 200 px) (3).png
TrialWire Patient Recruitment Platform that Reboots Stalled Clinical Trials announced as Multi-Award Finalist in the 2024 Citeline Awards
May 12, 2024 16:29 ET | TrialWire
The TrialWire™ Rapid Patient Recruitment Platform, the only pay-per-enrolled fixed-fee solution powered by AI and algorithms, has been select for 3 awards
Tevogen Logo Notified.png
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
May 10, 2024 17:40 ET | Tevogen Bio Inc
$50 million in financing advances operational objectives and bolsters a financial path to positive cashflow with minimal dilution.
Science 37 Logo.jpg
Science 37 Wins 2024 MedTech Breakthrough Award for “Clinical Efficiency Innovation”
May 09, 2024 10:00 ET | Science 37, Inc.
Science 37 announces its selection as the winner of the “Clinical Efficiency Innovation Award” in the 8th annual MedTech Breakthrough Awards program.
Alterity.png
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
May 08, 2024 07:25 ET | ALTERITY THERAPEUTICS LIMITED
 - ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, Australia and SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) --...